The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.
Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...
After hours: March 14 at 7:47:54 PM EDT Loading Chart for REGN ...
AN eye clinic is now open at the Metoreia Health Centre in the National Capital District.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback